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A B S T R A C T
Background
Vitamin C is an essential micronutrient and powerful antioxidant. Observational studies have shown an inverse relationship between
vitamin C intake and major cardiovascular events and cardiovascular disease (CVD) risk factors. Results from clinical trials are less
consistent.
Objectives
To determine the effectiveness of vitamin C supplementation as a single supplement for the primary prevention of CVD.
Search methods
We searched the following electronic databases on 11 May 2016: the Cochrane Central Register of Controlled Trials (CENTRAL) in
the Cochrane Library; MEDLINE (Ovid); Embase Classic and Embase (Ovid); Web of Science Core Collection (Thomson Reuters);
Database of Abstracts of Reviews of Effects (DARE); Health Technology Assessment Database and Health Economics Evaluations
Database in the Cochrane Library. We searched trial registers on 13 April 2016 and reference lists of reviews for further studies. We
applied no language restrictions.
Selection criteria
Randomised controlled trials of vitamin C supplementation as a single nutrient supplement lasting at least three months and involving
healthy adults or adults at moderate and high risk of CVD were included. The comparison group was no intervention or placebo. The
outcomes of interest were CVD clinical events and CVD risk factors.
Data collection and analysis
Two review authors independently selected trials for inclusion, abstracted the data and assessed the risk of bias.
Main results
We included eight trials with 15,445 participants randomised. The largest trial with 14,641 participants provided data on our primary
outcomes. Seven trials reported on CVD risk factors. Three of the eight trials were regarded at high risk of bias for either reporting or
attrition bias, most of the ’Risk of bias’ domains for the remaining trials were judged as unclear, with the exception of the largest trial
where most domains were judged to be at low risk of bias.
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The composite endpoint, major CVD events was not different between the vitamin C and placebo group (hazard ratio (HR) 0.99, 95%
confidence interval (CI) 0.89 to 1.10; 1 study; 14,641 participants; low-quality evidence) in the Physicians Health Study II over eight
years of follow-up. Similar results were obtained for all-cause mortality HR 1.07, 95% CI 0.97 to 1.18; 1 study; 14,641 participants;
very low-quality evidence, total myocardial infarction (MI) (fatal and non-fatal) HR 1.04 (95% CI 0.87 to 1.24); 1 study; 14,641
participants; low-quality evidence, total stroke (fatal and non-fatal) HR 0.89 (95% CI 0.74 to 1.07); 1 study; 14,641 participants; low-
quality evidence, CVD mortality HR 1.02 (95% 0.85 to 1.22); 1 study; 14,641 participants; very low-quality evidence, self-reported
coronary artery bypass grafting (CABG)/percutaneous transluminal coronary angioplasty (PTCA) HR 0.96 (95% CI 0.86 to 1.07); 1
study; 14,641 participants; low-quality evidence, self-reported angina HR 0.93 (95% CI 0.84 to 1.03); 1 study; 14,641 participants;
low-quality evidence.
The evidence for the majority of primary outcomes was downgraded (low quality) because of indirectness and imprecision. For all-
cause mortality and CVDmortality, the evidence was very low because more factors affected the directness of the evidence and because
of inconsistency.
Four studies did not state sources of funding, two studies declared non-commercial funding and two studies declared both commercial
and non-commercial funding.
Authors’ conclusions
Currently, there is no evidence to suggest that vitamin C supplementation reduces the risk of CVD in healthy participants and those
at increased risk of CVD, but current evidence is limited to one trial of middle-aged and older male physicians from the USA. There
is limited low- and very low-quality evidence currently on the effect of vitamin C supplementation and risk of CVD risk factors.
P L A I N L A N G U A G E S U M M A R Y
Vitamin C supplementation to prevent cardiovascular disease
Background
Cardiovascular diseases (CVD) are a group of conditions affecting the heart and blood vessels. CVD is a global burden and varies
between regions, and this variation has been linked in part to dietary factors. Such factors are important because they can be modified to
helpwith CVDprevention and management.This review assessed the effectiveness of vitamin C supplementation as a single supplement
at reducing cardiovascular death, all-cause death, non-fatal endpoints (such as heart attacks, strokes and angina) and CVD risk factors
in healthy adults and adults at high risk of CVD .
Study characteristics
We searched scientific databases for randomised controlled trials (clinical trials where people are allocated at random to one of two or
more treatments) looking at the effects of vitamin C supplementation in healthy adults or those at high risk of developing CVD. We
did not include people who already had CVD (e.g. heart attacks and strokes). The evidence is current to May 2016.
Key results
Eight trials fulfilled our inclusion criteria. One large trial looked at the effects of vitamin C supplements on the risk of major CVD
events (fatal and non-fatal) and found no beneficial effects. This trial was however conducted in middle-aged and older male doctors
in the USA and so its not certain that the effects are the same in other groups of people. Seven trials looked at the effects of vitamin C
supplements on CVD risk factors. We could not combine these trials as there was lots of missing information and differences between
the trials in terms of the participants recruited, the dose of vitamin C and the duration of trials. Overall, there were inconsistent
effects of vitamin C supplements on lipid levels and blood pressure and more research is needed. Four of the included studies did not
mention sources of funding of the study, two had non-commercial (grants) funding and two had both commercial (industries) and
non-commercial funding (grants).
Quality of the evidence
The evidence was of low or very low quality for major CVD events (myocardial infraction, stroke, angina and coronary artery bypass
grafting), all-cause mortality and CVDmortality. The evidence was of low quality because it was not applicable to the general population
(included only USA male physicians) and limited studies of vitamin C on the prevention of CVD.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vitamin C supplementation versus placebo for primary prevention of cardiovascular disease
Patient or population: middle-aged US male physicians
Settings: Not clear
Intervention: Vitamin C supplementat ion
Comparision: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Vitamin C supplemen-
tation
M ajor cardiovascular
event
Physicians
Follow-up: mean 8
years
86 per 1000 85 per 1000
(77 to 94)
HR 0.99
(0.89 to 1.10)
14,641
(1 study)
⊕⊕©©
low 1,2
Inconsistency was dif -
f icult to evaluate given
that one trial assessed
the primary outcome.
Grey literature search
is unlikely to intro-
duce publicat ion bias.
See Appendix 2 for
major cardiovascular
event checklist
Cardiovascular mortal-
ity
Physicians
Follow-up: mean 8
years
35 per 1000 35 per 1000
(29 to 42)
HR 1.02
(0.85 to 1.22)
14,641
(1 study)
⊕©©©
very low 1,2,3
Inconsistency was dif -
f icult to evaluate given
that one trial assessed
the primary outcome.
Grey literature search
is unlikely to intro-
duce publicat ion bias.
See Appendix 2 for
major cardiovascular
event checklist
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All- cause mortality
Physicians
Follow-up: mean 8
years
110 per 1000 117 per 1000
(107 to 128)
HR 1.07
(0.97 to 1.18)
14,641
(1 study)
⊕©©©
very low 1,2,3
Inconsistency was dif -
f icult to evaluate given
that one trial assessed
the primary outcome.
Grey literature search
is unlikely to intro-
duce publicat ion bias.
See Appendix 2 for
major cardiovascular
event checklist
Total myocardial in-
farction (fatal and non-
fatal)
Physicians
Follow-up: mean 8
years
34 per 1000 36 per 1000
(30 to 42)
HR 1.04
(0.87 to 1.24)
14,641
(1 study)
⊕⊕©©
low 1,2
Inconsistency was dif -
f icult to evaluate given
that one trial assessed
the primary outcome.
Grey literature search
is unlikely to intro-
duce publicat ion bias.
See Appendix 2 for
major cardiovascular
event checklist
Total stroke (fatal and
non- fatal)
Physicians
Follow-up: mean 8
years
34 per 1000 30 per 1000
(25 to 36)
HR 0.89
(0.74 to 1.07)
14,641
(1 study)
⊕⊕©©
low 1,2
Inconsistency was dif -
f icult to evaluate given
that one trial assessed
the primary outcome.
Grey literature search
is unlikely to intro-
duce publicat ion bias.
See Appendix 2 for
major cardiovascular
event checklist
Self- reported CABG/
PTCA
Part icipant self -reports
Follow-up: mean 8
years
97 per 1000 93 per 1000
(84 to 103)
HR 0.96
(0.86 to 1.07)
14,641
(1 study)
⊕⊕©©
low1,2
Inconsistency was dif -
f icult to evaluate given
that one trial assessed
the primary outcome.
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Self -reported outcomes
are unlikely to intro-
duce bias in this trial.
Grey literature search
is unlikely to intro-
duce publicat ion bias.
See Appendix 2 for
major cardiovascular
event checklist
Self- reported angina
Part icipant self -reports
Follow-up: mean 8
years
105 per 1000 98 per 1000
(89 to 108)
HR 0.93
(0.84 to 1.03)
14,641
(1 study)
⊕⊕©©
low 1,2
Inconsistency was dif -
f icult to evaluate given
that one trial assessed
the primary outcome.
Self -reported outcomes
are unlikely to intro-
duce bias in this trial.
Grey literature search
is unlikely to intro-
duce publicat ion bias.
See Appendix 2 for
major cardiovascular
event checklist
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; HR: Hazard rat io; CABG: coronary artery bypass graf t ing; PTCA: percutaneous transluminal coronary angioplasty
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Middle-aged US male physicians and is therefore not highly applicable to the decision context (downgraded by one for
indirectness).
2 Small number of included studies (n = 1) for these outcomes (downgraded by one for imprecision).
3 8 years follow-up (t imef rame) may not be suf f icient to detect mortality (downgraded by one for indirectness).
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B A C K G R O U N D
Description of the condition
Cardiovascular disease (CVD) remains the number one cause of
death globally (WHO 2011a). CVDs are the result of disorders
of the heart and blood vessels and include cerebrovascular dis-
ease, coronary heart disease (CHD), and peripheral arterial dis-
ease (PAD) (WHO 2011b). In 2008, an estimated 17.3 million
people died from CVDs, representing 30% of all global deaths.
Of these deaths, an estimated 7.3 million were due to CHD and
6.2 million were due to stroke (WHO 2011a). Over 80% of CVD
deaths occur in low- and middle-income countries, and the num-
ber of CVD deaths is expected to increase to 23.3 million by 2030
(Mathers 2006; WHO 2011a).
One of themain mechanisms thought to cause CVD is atheroscle-
rosis, in which the arteries become narrowed by plaques or athero-
mas (NHS 2012). Atherosclerosis can cause CVD when the ar-
teries are completely blocked by a blood clot or when blood flow
is restricted by a narrowed artery, limiting the amount of blood
and oxygen that can be delivered to organs or tissue (British Heart
Foundation 2012). Whilst arteries may naturally become harder
and narrower with age, this process may be accelerated by factors
such as smoking, high cholesterol, high blood pressure, obesity, a
sedentary lifestyle, and ethnicity (NHS 2012). Prevention of CVD
by targetingmodifiable factors remains a key public health priority.
Diet plays a major role in the aetiology of many chronic diseases
including CVD, thereby contributing to a significant geograph-
ical variability in morbidity and mortality rates across different
countries and populations worldwide (WHO 2003). A number of
dietary factors have been found to be associated with CVD risk,
such as a low consumption of fruit and vegetables (Begg 2007),
a high intake of saturated fat (Siri-Tarino 2010) and a high con-
sumption of salt (He 2011). Dietary factors are important since
they can be modified in order to lower CVD risk, making them
a prime target for interventions aimed at primary prevention and
management of CVD.
Description of the intervention
The intervention examined in this review is vitamin C supplemen-
tation as a single ingredient. No limit was placed on the dose or
frequency at which vitamin C is taken. Vitamin C (ascorbic acid
or ascorbate) is an essential micronutrient that acts as a power-
ful water-soluble antioxidant, reducing oxidative stress. It cannot
be synthesised in the body and is acquired primarily through the
consumption of fruit, vegetables, supplements, fortified beverages,
and fortified breakfast or ’ready-to-eat’ cereals (Frei 1989; WHO
2006).
Adults need 40 mg/day of vitamin C, which can be obtained from
a healthy diet. Supplementation of vitamin C up to 1000 mg per
day is unlikely to cause side effects (NHS choices 2015), whereas
larger amounts can cause stomach pain, diarrhoea and flatulence.
The pharmacokinetics of vitamin C are complex where the rela-
tionship between the amount ingested and plasma and tissue levels
is dependent on absorption, tissue transport, renal reabsorption
and excretion and rate of utilisation (Levine 2011). The dose con-
centration curve is sigmoidal with its steep portion between 30mg
and 100 mg of vitamin C daily. At doses greater than 100 mg/day,
plasma concentrations reach a plateau between 70 µmol/L and
80 µmol/L. At doses greater than 400 mg/day, further increases
in plasma concentrations are minimal (Levine 2011).
Data on the adverse effects of vitamin C supplementation show
that these are relatively rare. A survey of 9328 patients who used
high-dose intravenous vitamin C during the preceding 12 months
revealed that only 101 had side effects, mostly minor, including
lethargy/fatigue in 59 patients, change in mental status in 21 pa-
tients and vein irritation/phlebitis in six patients (Padayatty 2010).
In a recent meta-analysis of the effects of vitamin C supplemen-
tation, alone and in combination with other agents (such as vita-
min E, magnesium, zinc, selenium) on blood pressure (Juraschek
2012), few trials (six of 29) reported adverse effects, however de-
tails of these were not provided in the paper.
How the intervention might work
Population-based observational studies have shown an inverse as-
sociation between plasma vitamin C concentrations and vitamin
C intake with blood pressure (McCarron 1984; Moran 1993).
Observational studies have also shown an inverse relationship be-
tween vitamin C intake and mortality due to CVD (Jacques 1995;
Simon 1998). However, the results from randomised controlled
trials (RCTs) have not observed beneficial effects of vitamin C
supplementation in the prevention of cardiovascular events (Cook
2007; The Physicians Health Study II), or mortality outcomes
(Bjelakovic 2007).
Low-density lipoprotein (LDL) cholesterol in the blood may be
importantly atherogenic only after oxidative modification, which
allows it to be taken up by macrophages in the artery walls. These
macrophages, which are attracted to regions where oxidised LDL
is being taken up, become loaded with cholesterol (and are then
described as “foam cells” in the artery walls), leading to the de-
velopment of “fatty streaks”. Oxidised LDL can also be cytotoxic.
Antioxidants such as vitamin C can protect LDL from oxidative
modification and may help avoid CVD (Steinberg 1989).
A recent review has summarised the important functions of vita-
min C in the vascular bed in support of endothelial cells (May
2013). These functions include increasing the synthesis and depo-
sition of type IV collagen in the basement membrane, stimulating
endothelial proliferation, inhibiting apoptosis, scavenging radical
species, and sparing endothelial cell-derived nitric oxide to help
modulate blood flow. Endothelial dysfunction is an early sign of
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inflammatory disease such as atherosclerosis and vitamin C could
have a part to play in preventing these early stages.
In the early stages of atherosclerosis, monocytes adhere to the walls
of the endothelium, causing the vessel walls to thicken and lose
their elasticity. Research has shown that vitamin C supplementa-
tion can reduce the rate of monocyte adhesion to the endothelial
cell wall. A study looked at the effects of vitamin C (250 mg per
day, six weeks duration) in healthy adults with normal and below-
average plasma vitamin C concentration at baseline. Before the
study, participants with below average levels of vitaminChad 30%
greater monocyte adhesion than normal, putting them at higher
risk for atherosclerosis. After six weeks of vitamin C supplementa-
tion, the rate of monocyte adhesion fell by 37% (Woollard 2002).
Furthermore, intercellular adhesion molecule-1 (ICAM-1) is an
inducible surface glycoprotein that mediates the adhesion of
monocytes to the endothelium. The researchers went on to
demonstrate that the same dose and duration of vitamin C sup-
plementation was able to reduce monocyte ICAM-1 expression by
50% in participants with below-average plasma vitamin C con-
centration (Rayment 2003). Vitamin C supplementation might
improve nitric oxide bioactivity (Huang 2000), as well as en-
dothelial function of brachial and coronary arteries, as suggested
by short-term interventions among high-risk individuals (Grebe
2006; McNulty 2007; Silvestro 2002; Solzbach 1997).
Why it is important to do this review
A systematic review of the effects of individual vitamins and min-
erals, andmultivitamins, on clinical endpoints has been conducted
(Fortmann 2013). This review was conducted for the US Task
Force for Preventative Services. The authors found two trials of
vitamin C supplementation reporting clinical endpoints relevant
for CVD prevention, where no effect of the intervention was
found. In terms of effects on CVD risk factors, from preliminary
searching of the Cochrane Library, we identified five systematic
reviews in theDatabase of Abstracts of Reviews of Effects (DARE),
which assessed the effects of vitamin C supplementation on blood
pressure (Juraschek 2012; McRae 2006a; Ness 1997), low-density
lipid (LDL) cholesterol and triglycerides (McRae 2008), and to-
tal cholesterol (McRae 2006b). Only two of these included only
RCTs (Juraschek 2012; McRae 2008), the reminder include also
non-randomised experimental studies and observational studies.
The first review of RCTs covered both primary and secondary
prevention and the effects of vitamin C supplementation alone
and in combination with other agents (such as vitamin E, mag-
nesium, zinc, selenium) in trials between two and 26 weeks du-
ration (Juraschek 2012). The authors concluded that vitamin C
supplementation reduced systolic and diastolic blood pressure in
short-term trials. The second review concluded that supplemen-
tation with at least 500 mg/day of vitamin C, for a minimum
of four weeks, can result in a significant decrease in serum LDL
cholesterol and triglyceride concentrations. However, the lack of
quality assessment and analysis of statistical heterogeneity, and the
small sample sizes of the included trials, limit the reliability of the
authors’ conclusions (McRae 2008).
For the current review we examined evidence from RCTs of vita-
min C as a single supplement in the general population and those
at moderate to high risk of CVD. This review will update and
build on the existing systematic reviews discussed above by assess-
ing vitamin C supplementation (as a single supplement only) in
populations relevant for the primary prevention of CVD, in trials
of at least three months duration and assessing a wider range of
outcomes.
O B J E C T I V E S
To determine the effectiveness of vitamin C supplementation as
a single supplement for the primary prevention of cardiovascular
disease (CVD).
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) including cross-over tri-
als,studies reported as full-text, those published as abstract only,
and unpublished data were eligible for inclusion.
Types of participants
Healthy adults (18 years old or over) from the general popula-
tion and those at moderate to high risk of CVD (e.g. hyperten-
sion, hyperlipidaemia, overweight/obesity). As the review focuses
on the primary prevention of CVD, we excluded those who have
experienced a previous myocardial infarction (MI), stroke, revas-
cularisation procedure (coronary artery bypass grafting (CABG)
or percutaneous transluminal coronary angioplasty (PTCA)), and
those with angina or angiographically-defined coronary heart dis-
ease (CHD). If participants were at high risk of CVD they were
included if less than 25% of participants had CVD at baseline.
We also planned to exclude trials involving participants with type
2 diabetes, although this is a major risk factor for CVD, as inter-
ventions for the treatment and management of type 2 diabetes are
covered by reviews registered with the Cochrane Metabolic and
Endocrine Disorders Group.
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Types of interventions
The intervention was vitamin C supplements alone as a single
ingredient.No limitwas placed on the dose or frequency of vitamin
C taken. Trials were only considered where the comparison group
was placebo or no intervention.Multifactorial intervention studies
(including other additional interventions such as dietary changes
and exercise) were not included in this review, in order to avoid
confounding. If there had been a sufficient number of trials, we
also planned to stratify results by dose of vitamin C.
Types of outcome measures
We included studies with follow-up periods of at least three
months. Follow-up is considered to be the time elapsed since the
start of the intervention.
Primary outcomes
1. Major cardiovascular events
2. Cardiovascular mortality
3. All-cause mortality
4. Non-fatal endpoints such as MI, CABG, PTCA, angina, or
angiographically-defined CHD, stroke, carotid endarterectomy,
peripheral arterial disease (PAD)
Secondary outcomes
1. Changes in blood pressure (BP) (systolic (SBP) and
diastolic (DBP) and blood lipids (total cholesterol, high-density
lipid (HDL) cholesterol, low-density lipid (LDL) cholesterol,
triglycerides)
2. Occurrence of type 2 diabetes as a major CVD risk factor
3. Validated health-related quality of life measures
4. Adverse effects
5. Costs
Search methods for identification of studies
Electronic searches
We identified trials through systematic searches of the following
bibliographic databases on 11 May 2016:
1. Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library (2016, Issue 4 of 12)
2. Health Technology Assessment (HTA) in the Cochrane
Library (2016, Issue 2 of 4)
3. Database of Abstracts of Reviews of Effects (DARE) in the
Cochrane Library (2015, Issue 2 of 4)
4. NHS Economic Evaluation Database (NEED) in the
Cochrane Library (2015, Issue 2 of 4)
5. MEDLINE (Ovid, 1946 to April week 4 2016)
6. Embase Classic and Embase (Ovid, 1947 to 2016 Week 19)
7. Web of Science Core Collection (Thomson Reuters, 1970
to 11 May 2016)
We used Medical subject headings (MeSH) or equivalent and
text word terms. Searches were designed in accordance with the
Cochrane Heart Group methods and guidance.
The search strategies are detailed in Appendix 1. The Cochrane
sensitivity-maximising RCT filter (Lefebvre 2011) was applied to
MEDLINE (Ovid) and adaptations of it to the other databases,
except CENTRAL.
We searched all databases from their inception to the present, and
we imposed no restriction on language of publication.
Searching other resources
We checked reference lists of reviews for additional studies. We
searched ClinicalTrials.gov (http://www.clinicaltrials.gov/) and
the World Health Organization (WHO) International Clin-
ical Trials Registry platform (ICTRP) search portal (http://
apps.who.int/trialsearch/) for ongoing trials on 13 April 2016 us-
ing the search terms Vitamin C OR ascorbic acid AND cardio*.
Where necessary we contacted authors for any additional infor-
mation.
Data collection and analysis
Selection of studies
Two review authors (LA, LH, NF, RW, OG or KR) independently
screened for inclusion titles and abstracts of all the studies we
identified as a result of the search, and coded them as ’retrieve’
(eligible or potentially eligible/unclear) or ’do not retrieve’. We
retrieved the full-text study reports/publication and two review
authors (LA, LH, NF, RW, OG or KR) independently screened
the full-text and identified studies for inclusion, and identified and
recorded reasons for exclusion of the ineligible studies.We resolved
any disagreement through discussion or, if required, we consulted
a third author (KR/SS). We identified and excluded duplicates
and collated multiple reports of the same study so that each study
rather than each report was the unit of interest in the review. We
recorded the selection process in sufficient detail to complete a
PRISMA flow diagram (Figure 1) and ’Characteristics of excluded
studies’ table.
8Vitamin C supplementation for the primary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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Data extraction and management
Two review authors (LA, LH, NF, RW) independently extracted
study characteristics from included studies using a pre-standard-
ised data extraction form, and contacted chief investigators to re-
quest additional relevant information if necessary. We extracted
details of the study design, participant characteristics, study set-
ting, intervention (including dose and duration), and outcome
data including details of outcome assessment, adverse effects, and
methodological quality (randomisation, blinding, attrition) from
each of the included studies. We resolved disagreements by con-
sensus or by involving a third author (KR/SS). One author (NF)
transferred data into the Review Manager (RevMan 2012) file.
We double-checked that data were entered correctly by comparing
the data presented in the systematic review with the study reports.
A second author (KR/LA) spot-checked study characteristics for
accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (NF, RW) independently assessed the risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreements by discussion or by involving an-
other author (KR/SS). We assessed the risk of bias according to
the following domains.
1. Random sequence generation
2. Allocation concealment
3. Blinding of participants and personnel
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selective outcome reporting
7. Other bias (bias due to problems not covered elsewhere, e.g.
industry funding)
We graded each potential source of bias as having a ’low risk of
bias’, a ’high risk of bias’ or an ’unclear risk of bias’. Studies were
regarded as at high risk of bias if any of the domains listed above
were regarded at high risk of bias.
Assessment of bias in conducting the systematic review
We conducted the review according to the published protocol and
report any deviations from it in the ’Differences between protocol
and review’ section of the systematic review.
Measures of treatment effect
Datawere processed in accordancewith theCochraneHandbook for
Systematic Reviews of Interventions (Higgins 2011). We expressed
dichotomous outcomes as hazard ratios (HRs), with 95% confi-
dence intervals (CIs). For continuous outcomes, net changes were
compared (i.e. intervention group minus control group differ-
ences) and a mean difference (MD) and 95% CIs calculated for
each study.
Unit of analysis issues
Cross-over trials
We used data only from the first half of the trial as a parallel group
design.We only considered risk factor changes (i.e. blood pressure,
lipid levels) before patients crossed over to the other therapy and
where the duration was a minimum of three months before cross-
over occurred.
Studies with multiple intervention groups
Data for the control group were used for each intervention group
comparison. We reduced the weight assigned to the control group
by dividing the control group number (N) by the number of in-
tervention groups.
Cluster-randomised trials
If identified,we intended to analyse cluster-randomised trials using
the unit of randomisation (cluster) as the number of observations.
Where necessary, individual-level means and standard deviations
(SDs) adjusted for clustering would be utilised together with the
number of clusters in the denominator, in order to weight the
trials appropriately. We did not find any cluster-RCTs that met
the inclusion criteria for our review.
Dealing with missing data
We contacted investigators in order to verify key study character-
istics and obtain missing numerical outcome data where possible.
Missing data were captured in the data extraction form and re-
ported in the ’Risk of bias’ table. If a trial collected an outcome
measure at more than one time point, the longest period of follow-
up with 20% or fewer dropouts was utilised.
Assessment of heterogeneity
For each outcome, we conducted tests of heterogeneity using the
Chi2 test of heterogeneity and I2 statistic. Where there was no het-
erogeneity, a fixed-effect meta-analysis was performed. If moder-
ate to substantial heterogeneity was detected (40% to 100%), we
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looked for possible explanations for this (e.g. participants and in-
tervention). If the source of heterogeneity could not be explained,
we considered the following options: provide a narrative overview
and not aggregate the studies at all or use a random-effects model
with appropriate cautious interpretation.
Assessment of reporting biases
Had there been sufficient studies (10 ormore), we intended to plot
the trial effect against the standard error and present the results as
funnel plots (Sterne 2011). Since asymmetry could be caused by a
relationship between effect size and sample size or by publication
bias, we planned to examine any observed effect for clinical het-
erogeneity and carry out additional sensitivity tests (Sterne 2011).
There were insufficient trials to conduct this analysis.
Data synthesis
Statistical analysis was carried out using the Cochrane Collabora-
tion’s statistical software, (RevMan 2012).Dichotomous datawere
entered as events and the number of participants and continuous
data were entered as means and SDs. In the absence of moderate to
substantial heterogeneity (40% to 100%) and provided that there
were sufficient trials, we combined the results, using a fixed-effect
model. In the presence of substantial heterogeneity we plotted the
effects for individual trials in the forest plot but have not pooled
them statistically.
Subgroup analysis and investigation of heterogeneity
If there were sufficient trials (10 or more) we intended to stratify
results by high risk of CVD versus the general population, and
also by dose of vitamin C.
Sensitivity analysis
We planned to carry out sensitivity analyses with studies of six
months or more follow-up, and excluding studies at a high risk
of bias. Studies were regarded as at high risk of bias if any of the
domains in the risk of bias tool were regarded at high risk of bias.
Quality of evidence
We present the overall quality of the evidence for each outcome
according to the Grading of Recommendations Assessment, De-
velopment and Evaluation (GRADE) approach, which takes into
account issues not only related to internal validity (risk of bias,
inconsistency, imprecision, publication bias), but also to external
validity such as directness of results. Two review authors (LA, KR)
rated the quality for each outcome. We presented a summaries of
the evidence in Summary of findings for the main comparison,
which provides key information about the best estimate of the
magnitude of the effect, in relative terms for each relevant com-
parison of alternative management strategies, numbers of partici-
pants and trials addressing each important outcome, and the rat-
ing of the overall confidence in effect estimates for each outcome.
We created the ’Summary of findings’ table based on the methods
described in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011). We presented results on the outcomes
as described in Types of outcome measures.
In addition, we established an appendix ’Checklist to aid con-
sistency and reproducibility of GRADE assessments’ (Meader
2014) to help with standardisation of ’Summary of findings’ tables
(Appendix 2).
R E S U L T S
Description of studies
Results of the search
The searches generated 5555 hits after duplicates were removed.
Screening of titles and abstracts identified 227papers to go forward
for formal inclusion and exclusion. Of these, nine randomised
controlled trials (RCTs) met the inclusion criteria. There is one
trial in abstract form awaiting classification. Details of the flow of
studies through the review are shown in the PRISMAflowdiagram
in Figure 1.
Included studies
Details of the methods, participants, intervention, comparison
group and outcome measures for each of the studies included in
the review are shown in the Characteristics of included studies.
Eight trials were included randomising a total of 15,445 partici-
pants. The largest trial recruited males only (14,641 randomised)
(The Physicians Health Study II), six trials recruited male and fe-
male participants, and one trial did not specify the gender of par-
ticipants ( Mostafa 1989). The trials varied in the participants re-
cruited. Three trials recruited patients with hypercholesterolaemia
(ASAP Study; Cerna 1992; Jacques 1995), one trial recruited pa-
tientswith hypertension (Schindler 2003), one trial recruited older
participants aged 60 to 80 years, some with borderline or newly di-
agnosed hypertension (Fotherby 2000), one trial recruited healthy
young medical students aged 18 to 25 years (Menne 1975), an-
other recruited from a US University campus, but no details of
age were provided (Mostafa 1989), and the largest trial recruited
US male physicians aged 50 years or older at the start of the study
(The Physicians Health Study II), where some participants had
CVD risk factors (see Characteristics of included studies).
Two trials were conducted in Boston, MA, USA (Jacques 1995;
The Physicians Health Study II). The remaining studies were
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conducted in Bratislava, Czechoslovakia (Cerna 1992), the UK
(Fotherby 2000), South Africa (Menne 1975), Mississippi, USA
(Mostafa 1989), Kuopio, Eastern Finland (ASAP Study), and for
one trial this was unclear (Schindler 2003).
The duration of the intervention and follow-up periods varied
considerably from three months to eight years. The trial with the
longest intervention and follow-up period was eight years (The
Physicians Health Study II). This was followed by three years
(ASAP Study); two years (Schindler 2003), 18 months (Cerna
1992), eight months ( Jacques 1995), six months (Mostafa 1989),
four months (Menne 1975), and three months (Fotherby 2000).
In five of the trials the dose of vitamin C supplementation was
500 mg/day (ASAP Study; Cerna 1992; Fotherby 2000; Mostafa
1989; The Physicians Health Study II); in two trials the dose was
1 g/day (Jacques 1995; Menne 1975), and in the remaining trial
the dose was 2 g/day (Schindler 2003).
Details of the trial awaiting assessment is presented in the
Characteristics of studies awaiting classification table. This study
is only available as an abstract and we are awaiting responses from
the authors to our requests asking for further information.
Excluded studies
Details and reasons for exclusion for studies that closely missed the
inclusion criteria are provided in the Characteristics of excluded
studies table. Reasons for exclusion for the majority of studies in-
cluded alternative designs (not RCTs), short-term studies (< three
months), and no relevant outcomes (see Figure 1).
Risk of bias in included studies
Details are presented for the included trial in the ’Risk of bias’
tables in the Characteristics of included studies table and in Figure
2; Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
12Vitamin C supplementation for the primary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Only one study reported the method of random sequence gener-
ation which was regarded as at low risk of bias (The Physicians
Health Study II); for the remaining eight studies this was unclear.
No details were provided for the method of allocation conceal-
ment in all eight trials so this was judged to be at unclear risk of
bias.
Blinding
Five trials reported blinding participants and personnel and were
judged to be at low risk of performance bias (ASAP Study;
Fotherby 2000; Jacques 1995; Mostafa 1989; The Physicians
Health Study II). The remaining three studies were at unclear
risk of performance bias as blinding or participants and personnel
were not reported (Cerna 1992; Menne 1975; Schindler 2003).
Two trials were judged to be at low risk of detection bias as out-
come assessors were blind to group allocation (Fotherby 2000; The
Physicians Health Study II). For the remaining six trials blinding
of outcome assessors was not stated and this was judged to be
at unclear risk of bias (ASAP Study; Cerna 1992; Jacques 1995;
Menne 1975; Mostafa 1989; Schindler 2003).
Incomplete outcome data
There was a low risk of attrition bias in three trials (ASAP Study;
Jacques 1995; The Physicians Health Study II). In one trial there
was a high risk of attrition bias as no reasons for loss to follow-
up were given and the authors did not perform an intention-to-
treat analysis (Schindler 2003). For the remaining four studies this
was judged as unclear (Cerna 1992; Fotherby 2000; Menne 1975;
Mostafa 1989).
Selective reporting
Two studies were judged to be at high risk of reporting bias (ASAP
Study; Mostafa 1989). The first because no outcome data were
provided for total cholesterol, LDL cholesterol, triglycerides or
blood pressure (ASAP Study), the second because outcome data
were not provided for the control group (Mostafa 1989).
Other potential sources of bias
Therewas insufficient information to judge other potential sources
of bias and all studies were regarded as unclear risk of bias.
Effects of interventions
See: Summary of findings for the main comparison Vitamin
C supplementation versus placebo for primary prevention of
cardiovascular disease
Primary outcomes
One study provided data for all our primary outcomes (The
Physicians Health Study II). This was the largest study randomis-
ing 7329 US physicians to vitamin C supplementation and 7312
to the placebo group, with a mean follow-up period of eight years.
This trial was a factorial 2 x 2 trial of vitamin E and vitamin C
supplementation and it is therefore possible to compare two vita-
min C arms (active vitamin C and placebo vitamin E and active
vitamin C and active vitamin E) with two non-vitamin C arms
(placebo vitamin C and active vitamin E and placebo vitamin C
and E). The hazard ratios reported in this trial were adjusted for
a number of variables including age, study cohort (the original
Physicians study I or II), and vitamin E assignment. Results are
presented below using the inverse variance method.
A composite measure of major cardiovascular events was the pri-
mary end point in this trial including non-fatal myocardial in-
farction (MI), non-fatal stroke, and cardiovascular mortality. Re-
ported end points were confirmed in medical records and regis-
ters. The adjusted hazard ratios for this composite measure, all-
cause mortality, cardiovascular mortality, total MI (fatal and non-
fatal) and total stroke (fatal and non-fatal) are presented below and
graphically inAnalysis 1.1; Analysis 1.3; Analysis 1.2; Analysis 1.4;
Analysis 1.7) The authors of The Physicians Health Study II con-
cluded that there was no evidence that vitamin C supplementation
reduced the risk of major cardiovascular events and that these data
provide no support for the use of vitamin C supplements for the
prevention of cardiovascular disease (CVD) in middle-aged and
older men.
Major cardiovascular events
There was no effect of vitamin C supplementation on major car-
diovascular events at eight years follow-up hazard ratio (HR) 0.99
(95% confidence interval (CI) 0.89 to 1.10); 1 study; 14,641 par-
ticipants; lowquality of evidence (graphically presented inAnalysis
1.1).
Cardiovascular mortality
There was no substantial effect of vitamin C supplementation on
all cardiovascular morality HR 1.02 (95% CI 0.85 to 1.22); 1
study; 14,641 participants; very low quality of evidence (graphi-
cally presented in Analysis 1.2).
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Two deaths were reported in the ASAP Study, one in the vitamin C
group (subarachnoid haemorrhage) and one in the placebo group
(cardiac dysrhythmia). These data have not been incorporated in
the meta-analysis as the inverse variance method was used for the
The Physicians Health Study II to take account of the adjusted
hazard ratios for this study. In a separate analysis, incorporation of
these twodeaths hadno effect on the estimate as theThePhysicians
Health Study II had 99.9% of the weight.
All-cause mortality
There was no effect of vitamin C supplementation on all-cause
morality at eight years follow-up HR 1.07 (95% CI 0.97 to 1.18);
1 study; 14,641 participants; very low quality of evidence (graph-
ically presented in Analysis 1.3).
Total myocardial infraction
There was no effect of vitamin C on total myocardial infarction
(fatal and non-fatal events) HR 1.04 (95% CI 0.87 to 1.24); 1
study; 14,641 participants; low quality of evidence (graphically
presented in Analysis 1.4).
Self-reported revascularisation
There was nor effect of vitamin C supplementation on revasculari-
sation (coronary artery bypass grafting (CABG) and percutaneous
transluminal coronary angioplasty (PTCA)) at eight years follow-
up HR 0.96, 95% CI 0.86 to 1.07; 1 study, 14,641 participants;
low quality of evidence (graphically presented in Analysis 1.5).
Self-reported angina
There were no considerable effects of vitamin C supplementation
on self-reported angina symptomsHR 0.93, 95%CI 0.84 to 1.03,
1 study, 14,641 participants, low quality of evidence (graphically
presented in Analysis 1.6).
Total stroke
There was no effect of vitamin C supplementation on total stroke
(fatal and non-fatal events) at eight years follow-upHR 0.89 (95%
CI 0.74 to 1.07); 1 study; 14,641 participants; low quality of
evidence (graphically presented in Analysis 1.7).
Secondary outcomes
Cardiovascular risk factors
Seven studies (ASAP Study; Cerna 1992; Fotherby 2000; Jacques
1995; Menne 1975; Mostafa 1989; Schindler 2003) looked at our
secondary outcomes, but only three provided clear outcome data
that could be used in meta-analyses (Cerna 1992; Jacques 1995;
Schindler 2003). These three trials looked at the effect of vitamin
C on cholesterol (total cholesterol, HDL-cholesterol and LDL-
cholesterol), however, due to significant heterogeneity between the
trials (I2 =93%for total cholesterol, I2 =95%for LDL-cholesterol,
I2 = 66% for HDL-cholesterol, I2 = 47% for triglycerides), meta-
analyses were not performed. Data from these three trials were not
pooled but have been plotted to only show the graphical display.
For three studies (Cerna 1992; Jacques 1995; Schindler 2003), we
imputed standard deviation differences from baseline to follow-
up as these data were not available in the papers. To do this, we
followed the guidelines in the Cochrane Handbook for Systematic
Reviews of interventions for obtaining standard deviations from
standard errors (Higgins 2011, chapter 7.3.3) and have used a
correlation coefficient in these calculations of 0.5 as recommended
by Follman (Follman 1992 ). Results are described narratively and
the authors reports of the remaining four trials without usable data
are also described below.
Blood pressure
One trial reported data that could be used in a meta-analysis
(Analysis 1.8; Analysis 1.9). This trial reported no effects of vi-
tamin C supplementation on either systolic blood pressure (SBP)
(mean difference (MD) -1.00 mmHg, 95% CI -4.94 to 2.94;
16 participants) or diastolic blood pressure (DBP) (MD -2.00
mmHg, 95% CI -6.82 to 2.82; 16 participants) (Schindler 2003).
However, this study was extremely small, at high risk of attrition
bias so results should be treated with caution. Antihypertensive
medication was also used by some participants, which may have
impacted on the results obtained.
No control group data were provided for one trial so these were
not usable in a meta-analysis (Mostafa 1989).
One cross-over trial reported results over the whole trial period
and not in phases and so we were unable to incorporate the results
in the meta-analysis (Fotherby 2000). The authors reported that
clinic blood pressure did not change between the placebo and
vitamin C stages. Daytime ambulatory blood pressure showed a
smaller decrease in SBP of 2 ± 5.2 mmHg in comparison to DBP
1 ± 4.7 mmHg for 40 participants (Fotherby 2000).
For one study, blood pressure was reported at baseline but not at
follow-up (ASAP Study).
Lipid levels
For total cholesterol (Analysis 1.10), one of the three trials (Cerna
1992), showed that there was a reduction in total cholesterol with
vitamin C supplementation (MD -1.17 mmol/L. 95% CI -1.60
to -0.74; 1 study; 140 participants). The other two trials showed
no evidence of an effect of vitamin C supplementation on total
cholesterol (MD 0.02 mmol/L. 95% CI -0.18 to 0.22; 1 study;
138 participants) (Jacques 1995) and (MD 0.05 mmol/L. 95%
CI -0.14 to 0.24; 1 study; 16 participants) (Schindler 2003). The
reduction in lipid levels seen in the Cerna 1992 study compared
to others may be attributable to the high baseline levels of total
cholesterol and LDL-cholesterol.
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For LDL-cholesterol (Analysis 1.11), one trial (Cerna 1992),
showed that there was a significant reduction in LDL-cholesterol
with vitamin C supplementation (MD -1.27 mmol/L. 95% CI -
1.67 to -0.87; 136 participants). The other two trials showed no
evidence of effect of vitamin C supplementation on LDL-choles-
terol (MD 0.00 mmol/L. 95% CI -0.15 to 0.15; 1 study; 138
participants) (Jacques 1995) and (MD 0.16 mmol/L. 95% CI -
0.02 to 0.33; 1 study; 16 participants) (Schindler 2003).
For HDL-cholesterol (Analysis 1.12), two trials showed no effect
of vitamin C supplementation (MD 0.03 mmol/L. 95% CI -
0.09 to 0.15; 1 study; 136 participants Cerna 1992, and MD
0.00 mmol/L. 95% CI -0.06 to 0.06; 1 study; 138 participants
Jacques 1995), whilst the third showed a decrease in HDL with
the intervention (MD -0.13 mmol/L. 95% CI -0.23 to -0.03; 1
study; 16 participants Schindler 2003). This very small study was
however regarded at high risk of attrition bias (Schindler 2003).
Datawere also provided for theASAP Study (ASAPStudy) formen
and women reported separately at three years follow-up. We were
unable to combine these data in the meta-analysis as the numbers
randomised to each group were unclear in the report. The mean
HDL cholesterol increased in three years more among men who
received vitamin C supplement than in men who received placebo
(P = 0.025). In women, vitamin C had no effect on serum HDL
cholesterol at three years.
Three trials looked at the effect of vitamin C on triglycerides
(Fotherby 2000; Jacques 1995; Schindler 2003) and heterogene-
ity between studies was 47%. One trial showed no effect of vita-
min C supplementation on triglyceride levels (MD 0.05 mmol/L,
95% CI -0.14 to 0.24; 138 participants) (Jacques 1995), whilst
the other trial showed an increase in triglyceride levels with the
intervention (MD 0.23 mmol/L, 95% CI 0.07 to 0.38, 16 par-
ticipants) (Schindler 2003). This very small study was however
regarded at high risk of attrition bias (Schindler 2003) (Analysis
1.13). Pooling these studies using a random effectsmodel favoured
the placebo group but this did not reach statistical significance
(MD 0.15 mmol/L, 95% CI -0.02 to 0.32) (Analysis 1.13).
One cross-over trial reported results over the whole trial period
and not in phases and so we were unable to incorporate the results
in the meta-analysis (Fotherby 2000). For the total group of 40
participants, there was no difference between placebo and vitamin
C phases of the study for mean total cholesterol (6.2 ± 0.9 versus
6.2 ± 1.0 mmol/L; 40 participants), LDL cholesterol (3.6 ± 0.8
versus 3.5 ± 0.9mmol/L) andHDL cholesterol (1.53 ± 0.35 versus
1.56 ± 0.36 mmol/L). The authors did however find that when
they stratified by sex, there was an increase in HDL cholesterol
with vitamin C in women by 0.08 ± 0.36 mmol/L, but not in men
(Fotherby 2000).
For one study, total cholesterol, LDL cholesterol and triglycerides
are reported at baseline but not at follow-up (ASAP Study).
Type 2 diabetes
None of the included studies reported the occurrence of type 2
diabetes as a major CVD risk factor.
Health-related quality of life
None of the included studies reported validated health-related
quality of life measures.
Adverse effects
The Physicians Health Study II examined a series of adverse ef-
fects of both vitamin C and vitamin E supplementation com-
pared to placebo. No differences were seen in any of the following
outcomes: bleeding (because vitamin E may potentially inhibit
platelet function), gastrointestinal tract symptoms (peptic ulcer,
constipation, diarrhoea, gastritis, and nausea), fatigue, drowsiness,
skin discolouration or rashes andmigraine (The Physicians Health
Study II). Adverse effects were also reported in the ASAP Study.
These were described as death, serious adverse event and adverse
event with no further details given. No differences were seen be-
tween the vitamin C and placebo groups.
Cost
None of the included studies reported costs.
Subgroup analyses
There were insufficient trials (less than 10) to stratify results by
high risk of CVD versus the general population, and by dose of
vitamin C.
Sensitivity analyses
There were insufficient trials to conduct sensitivity analyses.
D I S C U S S I O N
Summary of main results
We included eight trials (15,445 participants randomised) from
the 5555 papers screened. The largest trial with 14,641 partici-
pants provided data on our primary outcomes, cardiovascular dis-
ease (CVD) clinical events (The Physicians Health Study II). One
smaller trial reported all-cause mortality as adverse events. Seven
trials reported on CVD risk factors. Three of these trials provided
data in a useable format for meta-analyses (Cerna 1992; Jacques
1995; Schindler 2003); the remaining four did not (ASAP Study;
Fotherby 2000; Menne 1975; Mostafa 1989). We attempted to
contact authors to provide missing details but were unsuccessful
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despite repeated attempts. Heterogeneity in the three trials pre-
cluded meta-analysis and we provide a narrative synthesis. Three
trials were regarded at high risk of bias for reporting bias (Schindler
2003), or attrition bias (ASAP Study; Mostafa 1989); most of the
risk of bias domains for the remaining trials were judged as un-
clear, with the exception of the largest trial where most domains
were judged to be at low risk of bias (The Physicians Health Study
II).
The composite endpoint major CVD events was not different be-
tween the vitamin C and placebo group in the Physicians Health
Study II and similar results were obtained for all-cause mortality,
total myocardial infarction (MI) (fatal and non-fatal) and total
stroke (fatal and non-fatal). The authors of this trial concluded
that vitamin C supplementation does not reduce the risk of major
CVD events over eight years of follow-up and should not be rec-
ommended for use in this group of participants - middle-aged and
older men (The Physicians Health Study II). Adverse events were
reported in this study and the ASAP Study with no significant
differences between the vitamin C and placebo groups.
There were variable and inconsistent effects of vitamin C supple-
mentation on CVD risk factors (lipid levels and blood pressure).
None of the trials reported our other secondary outcomes occur-
rence of type 2 diabetes as a major risk factor for CVD, health-
related quality of life and costs.
Overall completeness and applicability of
evidence
One large trial dominated this review and reports on our primary
outcomes (The Physicians Health Study II). Whilst the study is
adequately powered, the findings are limited to middle-aged and
oldermale physicians from theUSA. The participants had variable
baselineCVDrisk but no significant effectmodificationwas found
between vitamin C and baseline risk.
Seven trials reported on CVD risk factors (lipid levels and blood
pressure) with inconsistent findings. There were limitations in
the available data as only three trials provided data in a useable
format for meta-analyses, and for the remaining studies we were
unable to obtain additional information from the study authors.
The findings to date for these outcomes are inconclusive.
Quality of the evidence
We have presented the overall quality of the evidence for each
primary outcome according to the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) approach,
which takes into account issues not only related to internal validity
(risk of bias, inconsistency, imprecision, publication bias), but also
to external validity such as directness of results. All of the studies
included in this review were randomised controlled trials (RCTs).
There was no serious risk of bias detected for study limitations, in-
consistency and publication bias. Grey literature was not searched
but a comprehensive search across major databases and reference
lists of relevant studies was carried out, therefore we could not
formally assess these domains and they were not downgraded. The
evidence formajorCVDevent, totalMI, total stroke, self-reported
angina and self-reported coronary artery bypass grafting (CABG)/
percutaneous transluminal coronary angioplasty (PTCA) was of
low quality. The outcomes were downgraded by one for indirect-
ness (the populations were poorly applicable) and downgraded by
one for imprecision (small magnitude of the number of included
studies < five studies). The evidence for all-cause mortality and
CVD mortality was very low quality. The outcomes were down-
graded by two levels for indirectness (the populations were poorly
applicable, and the timeframe was insufficient), and downgraded
by one level for imprecision (small magnitude of the number of
included studies < five studies). Overall, inconsistency was diffi-
cult to evaluate because one trial was evaluated and therefore het-
erogeneity and the forest plot can not be evaluated (Summary of
findings for the main comparison).
Potential biases in the review process
Although OpenGrey was not screened due to limited resources, a
comprehensive search across major databases for interventions in-
volving vitamin C supplementation was carried out for this review.
In addition, the reference lists of systematic reviews were screened
and authors contacted for information when needed. All screen-
ing, inclusion and exclusion and data abstraction were carried out
independently by two review authors.
Multivitamins andmineral preparations including vitamin Cwere
excluded from this review because it would not be possible to dis-
entangle the specific effects of vitamin C. Multifactorial interven-
tions were excluded to avoid confounding. This did however limit
the number of trials that were eligible for inclusion.
Agreements and disagreements with other
studies or reviews
In terms of clinical events, only one trial was identified to exam-
ine the effects of vitamin C on CVD events for primary preven-
tion (The Physicians Health Study II). These results are however
restricted to middle-aged and older male physicians in the USA.
One further smaller trial reported all-cause mortality as adverse
events (ASAP Study), with only one event reported in each of the
vitamin C and placebo groups. Other trials have looked at the ef-
fects of vitamin C supplementation in women, but for secondary
rather than primary prevention of CVD (Cook 2007). There were
similar findings in terms of major CVD events. A recent system-
atic review of the effects of individual vitamins and minerals, and
multivitamins, on clinical endpoints has been conducted for the
US Task Force for Preventative Services. The authors found two
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trials of vitamin C supplementation reporting clinical endpoints
relevant for CVD prevention, where no effect of the intervention
was found (Fortmann 2013). These two trials are the same tri-
als reported in the current review (ASAP Study; The Physicians
Health Study II).
We were unable to determine the effectiveness of vitamin C sup-
plementation on major CVD risk factors (lipid levels and blood
pressure) with the trials included in the current version of the re-
view due to missing information, heterogeneity of participants,
dose of supplementation, duration of intervention and follow-up,
and methodological quality.
Previous systematic reviews of RCTs have examined the effects of
vitamin C supplementation alone and in combination with other
agents (such as vitamin E, magnesium, zinc, selenium) in trials
between two and26weeks duration (Juraschek 2012). The authors
concluded that vitamin C supplementation reduced systolic and
diastolic blood pressure in short-term trials. Another review of
RCTs concluded that supplementationwith at least 500mg/day of
vitamin C, for aminimum of four weeks, can result in a significant
decrease in serumLDLcholesterol and triglyceride concentrations.
However, the lack of quality assessment and analysis of statistical
heterogeneity, and the small sample sizes of the included trials,
limit the reliability of the authors’ conclusions (McRae 2008).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently, there is no evidence to suggest that vitamin C supple-
mentation reduces the risk of cardiovascular disease (CVD). How-
ever, the results of this review should be interpreted with caution
as the evidence was rated as low quality mainly for indirectness
(downgraded by one level) and imprecision (downgraded by one
level) for major CVD event, total myocardial infarction (MI), to-
tal stroke, self-reported angina and self-reported coronary artery
bypass grafting (CABG)/percutaneous transluminal coronary an-
gioplasty (PTCA). The evidence was rated as very low quality
mainly for very serious indirectness (downgraded by two levels)
and imprecision (downgraded by one level) for all-cause morality
and CVDmortality. Inconsistency of the evidence was difficult to
evaluate because only one trial was evaluated and therefore het-
erogeneity and the forest plot can not be evaluated.
Implications for research
Whilst a large adequately powered RCT reporting our primary
outcomes clearly showed no effect of vitamin C supplementation
on major CVD endpoints, these data are limited to middle-aged
and older male physicians from the USA. Future research should
report the effect of vitamin C supplements on type 2 diabetes and
use validated measures for quality of life. Future research should
report economic data, costs of vitamin C supplements should be
measured and reported as non of the trials reported costs. Fu-
ture research and reports should provide adequate and transpar-
ent methodological details such as sequence generation, allocation
concealment, blinding of outcomes assessors and report all out-
comes. Higher-quality trials are required as the current evidence
is of low and very low methodological quality. There is limited
evidence to date on the effects of vitamin C supplements on CVD
risk factors.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ASAP Study
Methods RCT of parallel group design
Participants ASAP trial. 520 smoking and non-smokingmen and postmenopausal women, aged 45 to
69 years, with hypercholesterolaemia (≥ 5.0 mmol/L) were recruited in Kuopio, Eastern
Finland
Recruitment was by multiple advertisements in the main local newspaper
Exclusion criteria:
· Premenopausal
· Had regular oestrogen substitution therapy
· Regular intake of antioxidants
· Acetosalicyclic acid or any other drug with antioxidative properties
· Severe obesity (BMI > 32k g/m2)
· Type 1 diabetes
· Uncontrolled hypertension (DBP > 105 mmHg)
· Any condition limiting mobility, making study visits impossible
· Severe disease shortening life expectancy
·Other disease or condition worsening the adherence to the measurements or treatment
Interventions Intervention (Vitamin C, n = 130): Slow-release ascorbic acid (250 mg) taken twice daily
Control (Placebo, n = 130): No details provided.
Follow-up: 3 years.
Outcomes Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, cardiovascular mor-
tality
Notes This was a 4-arm trial (placebo, vitamin E, vitamin C, vitamin C + E). We used the
placebo and vitamin C arms only. The focus of the study was to explore the effects of
vitamins C and E on atherosclerotic progression using the common carotid artery mean
intima media thickness (IMT)
Deaths from cardiovascular causes were specified as reasons for “drop-out”, however,
death from cardiovascular causes was not a pre-specified outcome measure
Men randomised to take vitamin C took more angina pectoris drugs than men in the
other groups (< 25% of participants had CVD at baseline so it met our criteria for
primary prevention)
Outcome data for total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides and
cardiovascular mortality were not reported in the paper. Review author NF attempted
to contact the authors using the email address provided in the paper but this was unde-
liverable (email address did not exist)
A later publication (Salonen 2003) reported change in HDL cholesterol in men and
women separately after 3 years of supplementation
Funding source: non-commercial (grants from the Academy of Finland Nos. 41258 and
52668)
Risk of bias Risk of bias
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ASAP Study (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised separately in four strata.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The study was double-masked. The masking was car-
ried out by the provider of the supplements (Ferrosan
A/S, Denmark) and delivered to the data centre of the
Field Centre, Research Institute of Public Health, Uni-
versity of Kuopio, after the completion of reading of the
videotapes of ultrasonographic examinations”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number of dropouts specified and reasons provided.
Selective reporting (reporting bias) High risk The authors state that they will measure total choles-
terol, LDL, triglycerides and blood pressure but do not
report outcomes
Other bias Unclear risk Insufficient information to judge.
Non-commercial funding.
Cerna 1992
Methods RCT of parallel group design
Participants 140 participants were recruited. Participants were employees of matador, ZTS Works
and the Retirement Office (Industrial plants and an organisation) situated in Bratislava,
Slovakia
Inclusion criteria:
·Men (mean age, 48 years) and women (mean age, 47 years)
· No signs of clinical problems
· Cholesterol > 6.2 mmol/L, Triacylglycerols >1.7 mmol/L, or mixed hyperlipaemia
Interventions Intervention (n = 83; 33 men and 50 women): Participants were provided Celaskon
effervescens Spofa at a dose of 500 mg/day, for 18 months
Control (n = 57; 24 men and 33 women): No details provided.
Outcomes Total cholesterol, LDL cholesterol, HDL cholesterol.
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Cerna 1992 (Continued)
Notes Review author NF could only find contact details for one of the authors, Emil Ginter.
NF contacted Emil Ginter to ask for further information on the control group, but who
was unable to help
Funding: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated.
Selective reporting (reporting bias) Low risk All outcomes reported as specified.
Other bias Unclear risk Insufficient information to judge.
Did not state funding.
Fotherby 2000
Methods RCT cross-over design
Participants 40 participants were recruited in the UK, from general practice lists
Inclusion criteria:
·Men and women
· Aged 60-80 years
· Non-smokers for >.10 years
· No history of vascular disease, i.e. no known stroke, myocardial infarction, angina or
peripheral vascular disease
·Not taking prescribed medications, including aspirin, non-steroidal anti-inflammatory
drugs or vitamin supplements
·Normotensive individuals and those with a history of borderline hypertension or newly
diagnosed hypertension, but who had never received treatment were included
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Fotherby 2000 (Continued)
Interventions Intervention: Vitamin C capsules (250 mg) twice daily, for 3 months
Control: Placebo capsules, twice daily, for 3 months.
After a 1 week ‘wash-out’ participants crossed to the alternative treatment for a further
3 months
Outcomes Systolic bloodpressure, diastolic bloodpressure, total cholesterol, LDL-cholesterol,HDL
cholesterol
Notes Our intention was to analyse this as parallel group, using data only from the first 3-
month intervention before patients crossed over to the other therapy, but insufficient
data were reported for us to be able to do this
Review author NF attempted to contact the first author, Dr Martin Fotherby, using the
email address provided in the paper but this was undeliverable (email address does not
exist). NF also contacted the last author, Dr Gordon Ferns who provided location details
for Dr Fotherby. An alternative email address was sought and NF attempted to contact
Dr Martin Fotherby on two occasions via email. We have not had a response and so the
results as reported in the paper are described narratively in text
Funding source: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and investigators involved with blood pressure
measurements and sample analysis were blinded to the treat-
ment each individual was receiving
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and investigators involved with blood pressure
measurements and sample analysis were blinded to the treat-
ment each individual was receiving
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The number of dropouts is unclear. The main paper says 40
completed the study but twoof the abstracts state 37 completed
Selective reporting (reporting bias) Low risk All outcomes reported as specified.
Other bias Unclear risk Insufficient information to judge
Did not state funding.
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Jacques 1995
Methods RCT of parallel group design.
Participants 155 participants (men and women, 20 to 65 years old) were recruited and screened
between December 1989 and September 1991 from two sources in Boston. Employees
of a large manufacturing complex were recruited by work site posters and presentations,
and Boston area residents were recruited by printed advertisements
Exclusion criteria:
· Age 20 or > 65 years
· Plasma ascorbic acid > 80 µmol/L for men or > 90 µmol/L for women
· HDL cholesterol > 1.4 mmol/L for men or >1.7 mmol/L for women
· Total cholesterol > 6.7 mmol/L
· Body mass index > 31 kg/m2 for men or > 33 kg/m2 for women
· Current smokers
· History of diabetes, heart disease or liver disease
· Vitamin C supplement use (> 60 mg/day) within the last 3 months
· Use of lipid altering medication
· On a weight modifying diet
Interventions Intervention (n = 80): 2 x 500 mg vitamin C tablets per day (one each morning and one
each evening) for 8 months
Control (n = 75): 2 x placebo tablets per day (one each morning and one each evening)
for 8 months
Outcomes Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides
Notes Funding: commercial and non-commercial (Hoffman-La Roche and US Department of
Agriculture)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk States “double-blind” but provide no further details.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers lost to follow-up provided, and reasons for
exclusions provided
Selective reporting (reporting bias) Low risk All outcomes reported as specified.
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Jacques 1995 (Continued)
Other bias Unclear risk Insufficient information to judge
Non-commercial and commercial funding. Authors
did state that the content of the study does not nec-
essarily represent the views of the US Department of
Agriculture
Menne 1975
Methods RCT of parallel group design
Participants 122 healthy, young medical students, (108 males and 14 females, 18-25 years of age)
were recruited from a South African University between April 1974 and August 1974
No further inclusion/exclusion criteria for participants was specified
Interventions Intervention (n = 62): Two 500 mg tablets of ascorbic acid, daily for four months
Control (n = 60): Two placebo tablets (500 mg citric acid), daily for four months
Outcomes Serum cholesterol, serum triglycerides.
Notes Outcome data were only displayed graphically and not reported in tables, therefore
insufficient for use in a meta-analysis
NF could not find any contact details for the authors of this paper
Funding source: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated. Just says “divided at random”.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States only participants were blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated.
Selective reporting (reporting bias) Low risk All outcomes reported as specified but in graphical not
numerical form
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Menne 1975 (Continued)
Other bias Unclear risk Insufficient information to judge.
Did not state funding.
Mostafa 1989
Methods RCT of parallel group design
Participants 67 volunteers, recruited at the University of Mississippi Campus, Mississippi, USA
No further inclusion/exclusion criteria for participants was specified
Interventions Intervention (n = 37): One 500 mg vitamin C tablet per day for 6 months. Particpants
were instructed to avoid taking vitamin C from other sources and it was emphasised that
they will not alter their diet habits or their lifestyle
Control (n = 30): Placebo, for 6 months (no further details provided)
Outcomes Systolic blood pressure, diastolic blood pressure, total cholesterol, LDL cholesterol, HDL
cholesterol, triglycerides
Notes Age, gender and ethnicity were not stated in the paper.
Outcome data for the control group were not provided in the paper and so data are
insufficient for use in meta-analyses. Before and after results where provided by the
authors are described in the results text
Review author NF could not find any contact details for the authors of this paper
Funding source: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double blind techniques were used to exclude the pos-
sibility of bias. Neither the subjects, nor staff knew
which subjects had taken the vitamin C or placebo reg-
imens”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details provided.
Selective reporting (reporting bias) High risk Outcome data were not reported for the control group.
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Mostafa 1989 (Continued)
Other bias Unclear risk Insufficient information to judge.
Did not state funding.
Schindler 2003
Methods RCT of parallel group design
Participants 20 participants with normal coronary angiograms (12 males, 8 females), with hyperten-
sion (SBP ≥ 145 mmHg)
Exclusion criteria:
· History of unstable angina pectoris
· Previous myocardial infarction
·Malignant hypertension
· Diabetes mellitus
· Evidence of glucose intolerance
· Cardiac autonomic neuropathy
· Valvular heart disease
· Peripheral vascular disease
· Significant endocrine, hepatic, renal, and inflammatory disease
· Regular dietary intake of antioxidants
Only patients not on vasoactive medication, such as angiotensin-converting enzyme
inhibitors, calcium channel blockers, or statins at baseline and/or throughout the study
period of two years, were recruited. In hypertensive patients, a regular intake of diuretics
and beta-blockers was allowed for blood pressure control. Each hypertensive patient
treated with beta-blockers discontinued the medication seven days before each study. In
addition, during this period, patients were asked to use a short-term calcium antagonist
to control high blood pressure. In these patients, study sessions were only performed if
patients did not use a short-acting calcium antagonist for at least 24 hours before the
investigation
Interventions Intervention (n = 12): 2 g vitamin C daily, for 2 years
Control (n = 8): Placebo supplementation daily, for two years
Outcomes Systolic blood pressure, diastolic blood pressure, total cholesterol, LDL cholesterol, very-
LDL cholesterol, HDL cholesterol, triglycerides
Notes 50 patients in total were included in the study, but only the hypertensive patients (n
= 20) were randomised into a vitamin C and placebo group. The remaining partici-
pants (chronic smokers, hypercholesterolaemic patients, and control participants) were
assigned to an open-label treatment with 2 g vitamin C daily during 2-year follow-up
During the study, hypertensive patients (n = 20, vitamin C and placebo groups) received
diuretics and three patients received combined therapy with beta-blockers
Paper does not state where participants were recruited from.
Funding source: non-commercial (grant from theGermanResearch Foundation [So 241/
2-2], the government of Baden-Württemberg for the “Center of Clinical Research II:
Cardiovascular Diseases-Analysis and Integration of Form und Function” at the Albert-
Ludwig- University Freiburg [Project: Sch-A1/A2 and EUN-A2] and a grant from the
Basel Heart Foundation of Switzerland)
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Schindler 2003 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information to judge (paper states that in-
vestigators were unaware of patients assignment to vita-
min C or placebo, but does not state whether patients
were aware, or not)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
High risk No reasons for loss to follow-up. No ITT analysis.
Selective reporting (reporting bias) Low risk All outcomes reported as specified.
Other bias Unclear risk Insufficient information to judge.
Non-commercial funding.
The Physicians Health Study II
Methods RCT of parallel group design
Participants 14,641 male participants were recruited in two phases.
Starting in July 1997, 7641 participants were recruited from Physicians Health Study I
In July 1999 recruitment of physicians started. Invitational letters were sent to US male
physicians identified from a list provided from the American Medical Association. 7000
willing and eligible men were recruited
Inclusion criteria:
·Men
· Age 50 years and older
·Willing to forego any current use ofmultivitamins or individual supplements containing
more than 100% RDA of vitamin E, vitamin C, β-carotene or vitamin A
Exclusion criteria:
· History of cirrhosis, active liver disease, taking anticoagulants
· A serious illness that would preclude participation
5.1% of participants had prevalent CVD at baseline (non-fatal MI and stroke). *Some
participants had a history of diabetes (approximately 6%), a history of high cholesterol
(approximately 36%), a history of hypertension (approximately 42%), a BMI ≥30 kg/
m2 (approximately 11%), were smokers (approximately 4%). Approximately 77% of
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The Physicians Health Study II (Continued)
participants were taking aspirin at baseline
*approximate percentages due to aggregated data
Interventions Intervention (Vitamin C (500 mg) taken daily, n = 7329)
Control (Placebo, n = 7312)
Mean follow-up was 8 years.
Outcomes Major cardiovascular events, total MI, MI death, total stroke, stroke death, Ischaemic
stroke, haemorrhagic stroke, cardiovascular death, congestive heart failure, angina, revas-
cularisation, all-cause mortality
Notes This trial was a factorial 2 x 2 trial of vitamin E and vitamin C supplementation and
it is therefore possible to compare two vitamin C arms (active vitamin C and placebo
vitamin E and active vitamin C and active vitamin E) with two non-vitamin C arms
(placebo vitamin C and active vitamin E and placebo vitamin C and E)
Funding source: commercial and non-commercial (grants from theNational Institutes of
Health, investigator-initiated grant fromBASFCorporation. Study agents and packaging
were provided by BASF Corporation, Wyeth Pharmaceuticals and DSM Nutritional
Products Inc)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated list of random numbers ran-
domised in blocks of 16, stratified by age, prior diagno-
sis of CVD and cancer, and for the PHSI subjects, by
their original β-carotene assignment”
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Treatment and follow-up continued in a blinded fash-
ion”, “All tablets were identical in appearance, size, and
color”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk End points were examined by physicians blinded to ran-
domised treatment assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers for participants dead, alive and unknown sta-
tus provided
Selective reporting (reporting bias) Low risk All outcomes reported as specified.
Other bias Unclear risk Insufficient information to judge.
Commercial and non-commercial funding, authors
clearly mention that commercial funding had no role in
the study
31Vitamin C supplementation for the primary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
BMI: body mass index
CVD: cardiovascular disease
DBP: diastolic blood pressure
HDL: high-density lipoprotein
ITT: intention-to-treat
LDL: low-density lipoprotein
MI: myocardial infarction
RCT: randomised controlled trial
RDA: recommended daily allowance
SBP: systolic blood pressure
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bassuk 2004 Secondary prevention trial (The Women’s Antioxidant Cardiovascular Study)
Boushehri 2012 Not a RCT
Bunpo 2015 Multifactorial intervention
Calzada 1995 Short term (8 weeks)
Dobson 1984 Not a RCT
Ghosh 1994 Short term (6 weeks)
Jayachandran 2000 Not a RCT
Osilesi 1991 Short term (6 weeks)
Schutte 2004 Intervention not vitamin C supplementation as a single supplement
Shidfar 2003 Short term (10 weeks)
RCT: randomised controlled trial
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Characteristics of studies awaiting assessment [ordered by study ID]
Nicolaides 2002
Methods RCT of parallel group design
Participants 1032 participants
Interventions Intervention (n = unspecified): Vitamin C (1g/day)
Control (n = unspecified): No treatment
Follow-up: 10 years
Outcomes Cardiovascular events
Notes This study is awaiting classification because only an abstract of the trial is available. The baseline health of participants
is unclear and more data are also needed on the cardiovascular events
Review author NF sought an email address of the author, AndrewNicolaides to ask if a full report had been published.
Andrew Nicolaides suggested to contact Dr Gianni Belcaro. NF emailed Dr Gianni Belcaro on two occasions. No
response has been received
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Vitamin C supplementation versus no intervention or placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Major cardiovascular event 1 Hazard Ratio (Fixed, 95% CI) 0.99 [0.89, 1.10]
2 Cardiovascular mortality 1 Hazard Ratio (Fixed, 95% CI) 1.02 [0.85, 1.22]
3 All-cause mortality 1 Hazard Ratio (Fixed, 95% CI) 1.07 [0.97, 1.18]
4 Total myocardial infarction 1 Hazard Ratio (Fixed, 95% CI) 1.04 [0.87, 1.24]
5 Self-reported CABG/PTCA 1 Hazard Ratio (Fixed, 95% CI) 0.96 [0.86, 1.07]
6 Self-reported angina 1 Hazard Ratio (Fixed, 95% CI) 0.93 [0.84, 1.03]
7 Total stroke 1 Hazard Ratio (Fixed, 95% CI) 0.89 [0.74, 1.07]
8 Systolic blood pressure (change
from baseline, mmHg)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9 Diastolic blood pressure (change
from baseline, mmHg)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10 Total cholesterol (change from
baseline, mmol/L)
3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11 LDL-cholesterol (change from
baseline, mmol/L)
3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12 HDL-cholesterol (change from
baseline, mmol/L)
3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13 Triglycerides (change from
baseline, mmol/L)
2 154 Mean Difference (IV, Random, 95% CI) 0.15 [-0.02, 0.32]
Analysis 1.1. Comparison 1 Vitamin C supplementation versus no intervention or placebo, Outcome 1
Major cardiovascular event.
Review: Vitamin C supplementation for the primary prevention of cardiovascular disease
Comparison: 1 Vitamin C supplementation versus no intervention or placebo
Outcome: 1 Major cardiovascular event
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
The Physicians Health Study II -0.0101 (0.0543) 100.0 % 0.99 [ 0.89, 1.10 ]
Total (95% CI) 100.0 % 0.99 [ 0.89, 1.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours vitamin C Favours placebo
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Analysis 1.2. Comparison 1 Vitamin C supplementation versus no intervention or placebo, Outcome 2
Cardiovascular mortality.
Review: Vitamin C supplementation for the primary prevention of cardiovascular disease
Comparison: 1 Vitamin C supplementation versus no intervention or placebo
Outcome: 2 Cardiovascular mortality
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
The Physicians Health Study II 0.0198 (0.093) 100.0 % 1.02 [ 0.85, 1.22 ]
Total (95% CI) 100.0 % 1.02 [ 0.85, 1.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours vitamin C Favours placebo
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Analysis 1.3. Comparison 1 Vitamin C supplementation versus no intervention or placebo, Outcome 3 All-
cause mortality.
Review: Vitamin C supplementation for the primary prevention of cardiovascular disease
Comparison: 1 Vitamin C supplementation versus no intervention or placebo
Outcome: 3 All-cause mortality
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
The Physicians Health Study II 0.0677 (0.0501) 100.0 % 1.07 [ 0.97, 1.18 ]
Total (95% CI) 100.0 % 1.07 [ 0.97, 1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours vitamin C Favours placebo
Analysis 1.4. Comparison 1 Vitamin C supplementation versus no intervention or placebo, Outcome 4
Total myocardial infarction.
Review: Vitamin C supplementation for the primary prevention of cardiovascular disease
Comparison: 1 Vitamin C supplementation versus no intervention or placebo
Outcome: 4 Total myocardial infarction
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
The Physicians Health Study II 0.0392 (0.0911) 100.0 % 1.04 [ 0.87, 1.24 ]
Total (95% CI) 100.0 % 1.04 [ 0.87, 1.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours vitamin C Favours placebo
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Analysis 1.5. Comparison 1 Vitamin C supplementation versus no intervention or placebo, Outcome 5 Self-
reported CABG/PTCA.
Review: Vitamin C supplementation for the primary prevention of cardiovascular disease
Comparison: 1 Vitamin C supplementation versus no intervention or placebo
Outcome: 5 Self-reported CABG/PTCA
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
The Physicians Health Study II -0.0408 (0.0561) 100.0 % 0.96 [ 0.86, 1.07 ]
Total (95% CI) 100.0 % 0.96 [ 0.86, 1.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours vitamin C Favours placebo
Analysis 1.6. Comparison 1 Vitamin C supplementation versus no intervention or placebo, Outcome 6 Self-
reported angina.
Review: Vitamin C supplementation for the primary prevention of cardiovascular disease
Comparison: 1 Vitamin C supplementation versus no intervention or placebo
Outcome: 6 Self-reported angina
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
The Physicians Health Study II -0.0726 (0.0519) 100.0 % 0.93 [ 0.84, 1.03 ]
Total (95% CI) 100.0 % 0.93 [ 0.84, 1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours vitamin C Favours placebo
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Analysis 1.7. Comparison 1 Vitamin C supplementation versus no intervention or placebo, Outcome 7
Total stroke.
Review: Vitamin C supplementation for the primary prevention of cardiovascular disease
Comparison: 1 Vitamin C supplementation versus no intervention or placebo
Outcome: 7 Total stroke
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
The Physicians Health Study II -0.1165 (0.0942) 100.0 % 0.89 [ 0.74, 1.07 ]
Total (95% CI) 100.0 % 0.89 [ 0.74, 1.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours vitamin C Favours placebo
Analysis 1.8. Comparison 1 Vitamin C supplementation versus no intervention or placebo, Outcome 8
Systolic blood pressure (change from baseline, mmHg).
Review: Vitamin C supplementation for the primary prevention of cardiovascular disease
Comparison: 1 Vitamin C supplementation versus no intervention or placebo
Outcome: 8 Systolic blood pressure (change from baseline, mmHg)
Study or subgroup Experimental Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schindler 2003 9 1 (3.464) 7 2 (4.359) -1.00 [ -4.94, 2.94 ]
-100 -50 0 50 100
Favours vitamin C Favours placebo
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Analysis 1.9. Comparison 1 Vitamin C supplementation versus no intervention or placebo, Outcome 9
Diastolic blood pressure (change from baseline, mmHg).
Review: Vitamin C supplementation for the primary prevention of cardiovascular disease
Comparison: 1 Vitamin C supplementation versus no intervention or placebo
Outcome: 9 Diastolic blood pressure (change from baseline, mmHg)
Study or subgroup Experimental Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schindler 2003 9 1 (6.245) 7 3 (3.464) -2.00 [ -6.82, 2.82 ]
-100 -50 0 50 100
Favours vitamin C Favours placebo
Analysis 1.10. Comparison 1 Vitamin C supplementation versus no intervention or placebo, Outcome 10
Total cholesterol (change from baseline, mmol/L).
Review: Vitamin C supplementation for the primary prevention of cardiovascular disease
Comparison: 1 Vitamin C supplementation versus no intervention or placebo
Outcome: 10 Total cholesterol (change from baseline, mmol/L)
Study or subgroup Experimental Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cerna 1992 83 -1.33 (1.505) 57 -0.16 (1.065) -1.17 [ -1.60, -0.74 ]
Jacques 1995 74 0.07 (0.516) 64 0.05 (0.64) 0.02 [ -0.18, 0.22 ]
Schindler 2003 9 0.103 (0.195) 7 0.05 (0.185) 0.05 [ -0.14, 0.24 ]
-4 -2 0 2 4
Favours vitamin C Favours control
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Analysis 1.11. Comparison 1 Vitamin C supplementation versus no intervention or placebo, Outcome 11
LDL-cholesterol (change from baseline, mmol/L).
Review: Vitamin C supplementation for the primary prevention of cardiovascular disease
Comparison: 1 Vitamin C supplementation versus no intervention or placebo
Outcome: 11 LDL-cholesterol (change from baseline, mmol/L)
Study or subgroup Experimental Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cerna 1992 81 -1.59 (1.347) 55 -0.32 (1.048) -1.27 [ -1.67, -0.87 ]
Jacques 1995 74 0 (0.43) 64 0 (0.48) 0.0 [ -0.15, 0.15 ]
Schindler 2003 9 0.259 (0.119) 7 0.1 (0.207) 0.16 [ -0.02, 0.33 ]
-4 -2 0 2 4
Favours vitamin C Favours control
Analysis 1.12. Comparison 1 Vitamin C supplementation versus no intervention or placebo, Outcome 12
HDL-cholesterol (change from baseline, mmol/L).
Review: Vitamin C supplementation for the primary prevention of cardiovascular disease
Comparison: 1 Vitamin C supplementation versus no intervention or placebo
Outcome: 12 HDL-cholesterol (change from baseline, mmol/L)
Study or subgroup Experimental Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cerna 1992 81 0.18 (0.362) 55 0.15 (0.342) 0.03 [ -0.09, 0.15 ]
Jacques 1995 74 0.01 (0.172) 64 0.01 (0.16) 0.0 [ -0.06, 0.06 ]
Schindler 2003 9 0 (0.078) 7 0.13 (0.113) -0.13 [ -0.23, -0.03 ]
-1 -0.5 0 0.5 1
Favours control Favours vitamin C
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Analysis 1.13. Comparison 1 Vitamin C supplementation versus no intervention or placebo, Outcome 13
Triglycerides (change from baseline, mmol/L).
Review: Vitamin C supplementation for the primary prevention of cardiovascular disease
Comparison: 1 Vitamin C supplementation versus no intervention or placebo
Outcome: 13 Triglycerides (change from baseline, mmol/L)
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Jacques 1995 74 0.11 (0.602) 64 0.06 (0.56) 44.7 % 0.05 [ -0.14, 0.24 ]
Schindler 2003 9 0.248 (0.189) 7 0.02 (0.135) 55.3 % 0.23 [ 0.07, 0.38 ]
Total (95% CI) 83 71 100.0 % 0.15 [ -0.02, 0.32 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.87, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 1.69 (P = 0.092)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours vitamin C Favours placebo
A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Library
#1 MeSH descriptor: [Ascorbic Acid] this term only
#2 ascorb*
#3 vit* near/6 c
#4 magnorbin
#5 hybrin
#6 #1 or #2 or #3 or #4 or #5
#7 MeSH descriptor: [Cardiovascular Diseases] explode all trees
#8 cardio*
#9 cardia*
#10 heart*
#11 coronary*
#12 angina*
#13 ventric*
#14 myocard*
#15 pericard*
#16 isch?em*
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#17 emboli*
#18 arrhythmi*
#19 thrombo*
#20 atrial next fibrillat*
#21 tachycardi*
#22 endocardi*
#23 (sick next sinus)
#24 MeSH descriptor: [Stroke] explode all trees
#25 (stroke or stokes)
#26 cerebrovasc*
#27 cerebral next vascular
#28 apoplexy
#29 (brain near/2 accident*)
#30 ((brain* or cerebral or lacunar) near/2 infarct*)
#31 MeSH descriptor: [Hypertension] explode all trees
#32 hypertensi*
#33 (peripheral next arter* next disease*)
#34 ((high or increased or elevated) near/2 blood pressure)
#35 MeSH descriptor: [Hyperlipidemias] explode all trees
#36 hyperlipid*
#37 hyperlip?emia*
#38 hypercholesterol*
#39 hypercholester?emia*
#40 hyperlipoprotein?emia*
#41 hypertriglycerid?emia*
#42 MeSH descriptor: [Arteriosclerosis] explode all trees
#43 MeSH descriptor: [Cholesterol] explode all trees
#44 cholesterol
#45 “coronary risk factor*”
#46 MeSH descriptor: [Blood Pressure] this term only
#47 “blood pressure”
#48 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #
25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43
or #44 or #45 or #46 or #47
#49 #6 and #48
MEDLINE
1. Ascorbic Acid/
2. ascorb*.tw.
3. (vit* adj6 c).tw.
4. magnorbin.tw.
5. hybrin.tw.
6. or/1-5
7. exp Cardiovascular Diseases/
8. cardio*.tw.
9. cardia*.tw.
10. heart*.tw.
11. coronary*.tw.
12. angina*.tw.
13. ventric*.tw.
14. myocard*.tw.
15. pericard*.tw.
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16. isch?em*.tw.
17. emboli*.tw.
18. arrhythmi*.tw.
19. thrombo*.tw.
20. atrial fibrillat*.tw.
21. tachycardi*.tw.
22. endocardi*.tw.
23. (sick adj sinus).tw.
24. exp Stroke/
25. (stroke or stokes).tw.
26. cerebrovasc*.tw.
27. cerebral vascular.tw.
28. apoplexy.tw.
29. (brain adj2 accident*).tw.
30. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
31. exp Hypertension/
32. hypertensi*.tw.
33. peripheral arter* disease*.tw.
34. ((high or increased or elevated) adj2 blood pressure).tw.
35. exp Hyperlipidemias/
36. hyperlipid*.tw.
37. hyperlip?emia*.tw.
38. hypercholesterol*.tw.
39. hypercholester?emia*.tw.
40. hyperlipoprotein?emia*.tw.
41. hypertriglycerid?emia*.tw.
42. exp Arteriosclerosis/
43. exp Cholesterol/
44. cholesterol.tw.
45. “coronary risk factor* ”.tw.
46. Blood Pressure/
47. blood pressure.tw.
48. or/7-47
49. randomized controlled trial.pt.
50. controlled clinical trial.pt.
51. randomized.ab.
52. placebo.ab.
53. drug therapy.fs.
54. randomly.ab.
55. trial.ab.
56. groups.ab.
57. 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56
58. exp animals/ not humans.sh.
59. 57 not 58
60. 6 and 48 and 59
Embase
1. ascorbic acid/
2. ascorb*.tw.
3. (vit* adj6 c).tw.
4. magnorbin.tw.
5. hybrin.tw.
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6. or/1-5
7. exp cardiovascular disease/
8. cardio*.tw.
9. cardia*.tw.
10. heart*.tw.
11. coronary*.tw.
12. angina*.tw.
13. ventric*.tw.
14. myocard*.tw.
15. pericard*.tw.
16. isch?em*.tw.
17. emboli*.tw.
18. arrhythmi*.tw.
19. thrombo*.tw.
20. atrial fibrillat*.tw.
21. tachycardi*.tw.
22. endocardi*.tw.
23. (sick adj sinus).tw.
24. exp cerebrovascular disease/
25. (stroke or stokes).tw.
26. cerebrovasc*.tw.
27. cerebral vascular.tw.
28. apoplexy.tw.
29. (brain adj2 accident*).tw.
30. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
31. exp hypertension/
32. hypertensi*.tw.
33. peripheral arter* disease*.tw.
34. ((high or increased or elevated) adj2 blood pressure).tw.
35. exp hyperlipidemia/
36. hyperlipid*.tw.
37. hyperlip?emia*.tw.
38. hypercholesterol*.tw.
39. hypercholester?emia*.tw.
40. hyperlipoprotein?emia*.tw.
41. hypertriglycerid?emia*.tw.
42. exp Arteriosclerosis/
43. exp Cholesterol/
44. cholesterol.tw.
45. “coronary risk factor*”.tw.
46. Blood Pressure/
47. blood pressure.tw.
48. or/7-47
49. 6 and 48
50. random$.tw.
51. factorial$.tw.
52. crossover$.tw.
53. cross over$.tw.
54. cross-over$.tw.
55. placebo$.tw.
56. (doubl$ adj blind$).tw.
57. (singl$ adj blind$).tw.
58. assign$.tw.
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59. allocat$.tw.
60. volunteer$.tw.
61. crossover procedure/
62. double blind procedure/
63. randomized controlled trial/
64. single blind procedure/
65. 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64
66. (animal/ or nonhuman/) not human/
67. 65 not 66
68. 49 and 67
69. limit 68 to embase
Web of Science
# 12 #11 AND #10
# 11 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
# 10 #9 AND #8
# 9 TS=(ascorb* or (vit* near/6 c) or magnorbin or hybrin)
# 8 #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
# 7 TS=(hyperlipid* OR hyperlip?emia*OR hypercholesterol*OR hypercholester?emia*OR hyperlipoprotein?emia*OR hypertriglyc-
erid?emia*)
# 6 TS=(“high blood pressure”)
# 5 TS=(hypertensi* OR “peripheral arter* disease*”)
# 4 TS=(stroke OR stokes OR cerebrovasc* OR cerebral OR apoplexy OR (brain SAME accident*) OR (brain SAME infarct*))
# 3 TS=(“atrial fibrillat*” OR tachycardi* OR endocardi*)
# 2 TS=(pericard* OR isch?em* OR emboli* OR arrhythmi* OR thrombo*)
# 1 TS=(cardio* OR cardia* OR heart* OR coronary* OR angina* OR ventric* OR myocard*)
Appendix 2. Checklist to aid consistency and reproducibility of GRADE assessments
Major CVD
event
All-cause
mortality
CVD mor-
tality
Total MI Total stroke Self-
reported
angina
Self-
reported
CABG/
PTCA
Study limi-
tations
(risk of
bias)
1. Was ran-
dom se-
quence gen-
era-
tion used (i.
e. no poten-
tial for selec-
tion bias)?
Yes Yes Yes Yes Yes Yes Yes
2. Was allo-
cation con-
cealment
used (i.e. no
potential for
Unclear Unclear Unclear Unclear Unclear Unclear Unclear
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(Continued)
selection
bias)?
3. Was there
blinding of
participants
and person-
nel (i.e. no
potential for
perfor-
mance bias)?
Yes Yes Yes Yes Yes Yes Yes
4. Was there
blinding of
outcome as-
sessment (i.
e. no poten-
tial for de-
tection bias)
?
Yes Yes Yes Yes Yes Yes Yes
5.
Was an ob-
jective out-
come used?
Yes (end
points were
examined by
physicians)
Yes (end
points were
examined by
physicians)
Yes (end
points were
examined by
physicians)
Yes (end
points were
examined by
physicians)
Yes (end
points were
examined by
physicians)
No (unlikely
to introduce
bias because
it was a dou-
ble-blinded
trial)
No (unlikely
to introduce
bias because
it was a dou-
ble-blinded
trial)
6. Were
more than
80% of par-
ticipants en-
rolled in tri-
als included
in the anal-
ysis (i.e. no
potential re-
porting bias)
?a
Yes Yes Yes Yes Yes Yes Yes
7. Were data
re-
ported con-
sistently for
the outcome
of interest (i.
e. no poten-
tial selective
reporting)?
Yes Yes Yes Yes Yes Yes Yes
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(Continued)
8. No other
biases
reported (i.
e. no poten-
tial of other
bias)?
Unclear Unclear Unclear Unclear Unclear Unclear Unclear
9. Did the
trials end up
as scheduled
(i.e.
not stopped
early)?
Yes Yes Yes Yes Yes Yes Yes
Inconsis-
tency
1. Point esti-
mates
did not vary
widely?
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
2.
To what ex-
tent did con-
fidence in-
tervals over-
lap (substan-
tial: all con-
fi-
dence inter-
vals overlap
at least one
of the in-
cluded stud-
ies point es-
timate;
some: confi-
dence inter-
vals overlap
but
not all over-
lap at least
one point es-
timate;
no: at least
one outlier:
where the
confi-
dence inter-
val of some
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
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(Continued)
of the stud-
ies do not
overlap with
those
of most in-
cluded stud-
ies)?
3. Was the
direc-
tion of effect
consistent?
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
Not applica-
ble (one trial
in forest
plot)
4. What was
the magni-
tude of sta-
tistical het-
erogeneity
(asmeasured
by I²) - low
(I² < 40%),
moderate (I²
40% to
60%), high
I² > 60%)?
Not applica-
ble (cannot
calculate I2
for one trial)
Not applica-
ble (cannot
calculate I2
for one trial)
Not applica-
ble (cannot
calculate I2
for one trial)
Not applica-
ble (cannot
calculate I2
for one trial)
Not applica-
ble (cannot
calculate I2
for one trial)
Not applica-
ble (cannot
calculate I2
for one trial)
Not applica-
ble (cannot
calculate I2
for one trial)
5. Was the
test for het-
ero-
geneity sta-
tistically sig-
nificant (P <
0.1)?
Not applica-
ble (one trail
meta-
analysed)
Not applica-
ble (one trail
meta-
analysed)
Not applica-
ble (one trail
meta-
analysed)
Not applica-
ble (one trail
meta-
analysed)
Not applica-
ble (one trail
meta-
analysed)
Not applica-
ble (one trail
meta-
analysed)
Not applica-
ble (one trail
meta-
analysed)
Indirect-
ness
1. Were the
popu-
lations in in-
cluded stud-
ies applica-
ble to the de-
cision con-
text?
Poorly
appli-
cable (mid-
dle aged US
male physi-
cians) ()
Poorly
appli-
cable (mid-
dle aged US
male physi-
cians) ()
Poorly
appli-
cable (mid-
dle aged US
male physi-
cians) ()
Poorly
appli-
cable (mid-
dle aged US
male physi-
cians) ()
Poorly
appli-
cable (mid-
dle aged US
male physi-
cians) ()
Poorly
appli-
cable (mid-
dle aged US
male physi-
cians) ()
Poorly
appli-
cable (mid-
dle aged US
male physi-
cians) ()
2. Were the
inter-
ventions in
the included
studies
applicable to
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
Highly ap-
plicable
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(Continued)
the decision
context?
3. Was
the included
outcomenot
a surrogate
outcome?
Yes Yes Yes Yes Yes Yes Yes
4.
Was the out-
come time-
frame suffi-
cient?
Sufficient Insuffi-
cient (longer
timeframe
may be nec-
essary to
cover the
critical eti-
ologic win-
dow or pro-
vide a
sufficient
cumulative
dose capable
of
prevent-
ing cardio-
vascular dis-
ease) ()
Insuffi-
cient (longer
timeframe
may be nec-
essary to
cover the
critical eti-
ologic win-
dow or pro-
vide a
sufficient
cumulative
dose capable
of
prevent-
ing cardio-
vascular dis-
ease) ()
Sufficient Sufficient Sufficient Sufficient
5. Were the
conclusions
based on di-
rect compar-
isons?
Yes Yes Yes Yes Yes Yes Yes
Impreci-
sion
1. Was the
confi-
dence inter-
val for the
pooled
estimate not
con-
sistent with
benefit?
Diffi-
cult to judge
(one trial)
Diffi-
cult to judge
(one trial)
Diffi-
cult to judge
(one trial)
Diffi-
cult to judge
(one trial)
Diffi-
cult to judge
(one trial)
Diffi-
cult to judge
(one trial)
Diffi-
cult to judge
(one trial)
2. What is
the magni-
tude of the
me-
dian sample
size (high:
High High High High High High High
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(Continued)
300 partici-
pants, inter-
me-
diate: 100-
300 partici-
pants, low: <
100 partici-
pants)?a
3. What was
the magni-
tude
of the num-
ber of in-
cluded stud-
ies (large:
>10 studies,
moderate: 5-
10 stud-
ies, small: <5
studies)?a
Small () Small () Small () Small () Small () Small () Small ()
4. Was
the outcome
a common
event (e.g.
occurs more
than 1/100)
?
Yes Yes Yes Yes Yes Yes Yes
Publication
bias
1.
Was a com-
prehensive
search con-
ducted?
Yes Yes Yes Yes Yes Yes Yes
2. Was grey
literature
searched?
No (Open-
Grey search
was not con-
ducting due
to limited
resources)
No (Open-
Grey search
was not con-
ducting due
to limited
resources)
No (Open-
Grey search
was not con-
ducting due
to limited
resources)
No (Open-
Grey search
was not con-
ducting due
to limited
resources)
No (Open-
Grey search
was not con-
ducting due
to limited
resources)
No (Open-
Grey search
was not con-
ducting due
to limited
resources)
No (Open-
Grey search
was not con-
ducting due
to limited
resources)
3. Were no
restrictions
applied to
study selec-
tion on the
basis of lan-
guage?
Yes Yes Yes Yes Yes Yes Yes
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(Continued)
4. There was
no industry
influence on
studies
included in
the review?
Yes (inter-
vention
providers
had no role
in the study
design; con-
duct
of the study;
collection,
manage-
ment, analy-
sis, and in-
terpretation
of
the data; or
prepara-
tion, review,
or approval
of the
manuscript)
Yes (inter-
vention
providers
had no role
in the study
design; con-
duct
of the study;
collection,
manage-
ment, analy-
sis, and in-
terpretation
of
the data; or
prepara-
tion, review,
or approval
of the
manuscript)
Yes (inter-
vention
providers
had no role
in the study
design; con-
duct
of the study;
collection,
manage-
ment, analy-
sis, and in-
terpretation
of
the data; or
prepara-
tion, review,
or approval
of the
manuscript)
Yes (inter-
vention
providers
had no role
in the study
design; con-
duct
of the study;
collection,
manage-
ment, analy-
sis, and in-
terpretation
of
the data; or
prepara-
tion, review,
or approval
of the
manuscript)
Yes (inter-
vention
providers
had no role
in the study
design; con-
duct
of the study;
collection,
manage-
ment, analy-
sis, and in-
terpretation
of
the data; or
prepara-
tion, review,
or approval
of the
manuscript)
Yes (inter-
vention
providers
had no role
in the study
design; con-
duct
of the study;
collection,
manage-
ment, analy-
sis, and in-
terpretation
of
the data; or
prepara-
tion, review,
or approval
of the
manuscript)
Yes (inter-
vention
providers
had no role
in the study
design; con-
duct
of the study;
collection,
manage-
ment, analy-
sis, and in-
terpretation
of
the data; or
prepara-
tion, review,
or approval
of the
manuscript)
5. There was
no evidence
of
funnel plot
asymmetry?
Not applica-
ble
Not applica-
ble
Not applica-
ble
Not applica-
ble
Not applica-
ble
Not applica-
ble
Not applica-
ble
6. There was
no dis-
crepancy in
findings be-
tween pub-
lished
and unpub-
lished trials?
Not applica-
ble
Not applica-
ble
Not applica-
ble
Not applica-
ble
Not applica-
ble
Not applica-
ble
Not applica-
ble
aDepends on the context of the systematic review area
(): key item for potential downgrading the quality of the evidence (GRADE) as shown in the footnotes of the ’Summary of finding’
table(s); GRADE: Grading of Recommendations Assessment, Development and Evaluation; N/A: not applicable
aDepends on the
systematic review
(): key item for potential
grading the quality
idence (GRADE)
the footnotes of the
of finding’ table(s);
Grading of Recommendations
Assessment, Development
Evaluation; N/A:
ble
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